Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Capecitabine or S-1 in Oligometastatic Nasopharyngeal Carcinoma
NCT04319471Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and tegafur in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
capecitabinetegafur
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04319471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319471.